Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Payables (2016 - 2021)

GT Biopharma (GTBP) has disclosed Payables for 12 consecutive years, with $2.8 million as the latest value for Q3 2021.

  • On a quarterly basis, Payables rose 29.06% to $2.8 million in Q3 2021 year-over-year; TTM through Sep 2021 was $2.8 million, a 29.06% increase, with the full-year FY2020 number at $2.2 million, up 15.62% from a year prior.
  • Payables was $2.8 million for Q3 2021 at GT Biopharma, up from $1.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.8 million in Q3 2021 to a low of -$9000.0 in Q3 2017.
  • A 5-year average of $2.0 million and a median of $2.0 million in 2017 define the central range for Payables.
  • Peak YoY movement for Payables: tumbled 100.5% in 2017, then soared 25111.11% in 2018.
  • GT Biopharma's Payables stood at $2.5 million in 2017, then fell by 11.59% to $2.3 million in 2018, then decreased by 13.82% to $1.9 million in 2019, then rose by 15.62% to $2.2 million in 2020, then rose by 24.92% to $2.8 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Payables are $2.8 million (Q3 2021), $1.5 million (Q2 2021), and $2.4 million (Q1 2021).